Ovid Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 8, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 8, 2024
OVID$2.85+10.5%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| For the Year Ended December 31, 2023 | For the Year Ended December 31,2022 | |
|---|---|---|
| Revenue: | ||
| License and other revenue | $391,695 | $1,502,748 |
| Total revenue | 391,695 | 1,502,748 |
| Operating expenses: | ||
| Research and development | 28,587,884 | 24,618,399 |
| General and administrative | 31,085,274 | 32,432,510 |
| Total operating expenses | 59,673,158 | 57,050,909 |
| Loss from operations | (59,281,464) | (55,548,161) |
| Other income (expense), net | 6,942,505 | 1,379,132 |
| Loss before provision for income taxes | $(52,338,959) | $(54,169,029) |
| Provision for income taxes | — | — |
| Net loss | $(52,338,959) | $(54,169,029) |
| Net loss per share, basic | $(0.74) | $(0.77) |
| Net loss per share, diluted | $(0.74) | $(0.77) |
| Weighted-average common shares outstanding, basic | 70,580,604 | 70,424,819 |
| Weighted-average common shares outstanding, diluted | 70,580,604 | 70,424,819 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.